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Abstract
Background: In this study, instead of current biochemical methods, the effects of deleterious amino acid
substitutions in F8 and F9 gene upon protein structure and function were assayed by means of computational
methods and information from the databases. Deleterious substitutions of F8 and F9 are responsible for
Haemophilia A and Haemophilia B which is the most common genetic disease of coagulation disorders in blood.
Yet, distinguishing deleterious variants of F8 and F9 from the massive amount of nonfunctional variants that occur
within a single genome is a significant challenge.
Methods: We performed an in silico analysis of deleterious mutations and their protein structure changes in order
to analyze the correlation between mutation and disease. Deleterious nsSNPs were categorized based on empirical
based and support vector machine based methods to predict the impact on protein functions. Furthermore, we
modeled mutant proteins and compared them with the native protein for analysis of protein structure stability.
Results: Out of 510 nsSNPs in F8, 378 nsSNPs (74%) were predicted to be ‘intolerant’ by SIFT, 371 nsSNPs (73%)
were predicted to be ‘damaging’ by PolyPhen and 445 nsSNPs (87%) as ‘less stable’ by I-Mutant2.0. In F9, 129
nsSNPs (78%) were predicted to be intolerant by SIFT, 131 nsSNPs (79%) were predicted to be damaging by
PolyPhen and 150 nsSNPs (90%) as less stable by I-Mutant2.0. Overall, we found that I-Mutant which emphasizes
support vector machine based method outperformed SIFT and PolyPhen in prediction of deleterious nsSNPs in
both F8 and F9.
Conclusions: The models built in this work would be appropriate for predicting the deleterious amino acid
substitutions and their functions in gene regulation which would be useful for further genotype-phenotype
researches as well as the pharmacogenetics studies. These in silico tools, despite being helpful in providing
information about the nature of mutations, may also function as a first-pass filter to determine the substitutions
worth pursuing for further experimental research in other coagulation disorder causing genes.
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Background
Hereditary haemophilias are the most frequently
encountered recessive inherited disease of coagulation
disorders in blood. Haemophilia A and Haemophilia B
are X-linked inherited bleeding disorder caused by a
decreased activity or lack of coagulation factor VIII
cofactor activity (haemophilia A) or coagulation factor
IX enzyme activity (haemophilia B) due to heterogenous
mutations in the F8 and F9 coding gene [1,2]. Factor
VIII is a protein cofactor with no enzyme activity that,
when activated, forms a complex with factor IXa serine
protease on membrane surfaces. Upon activation, and in
the presence of calcium ions and phospholipid surfaces,
factor VIII and factor IX form an active complex, the
tenase complex, which activates factor X during blood
coagulation [3]. The F8 gene maps to the distal end of
the long arm of X-chromosome (Xq28) and spans 186
Correspondence: georgecp77@yahoo.co.in
† Contributed equally
Centre for Nanobiotechnology, Medical Biotechnology Division, School of
Bio Sciences and Technology, VIT University, Vellore 632014, Tamil Nadu,
India
C Journal of Biomedical Science 2012, 19:30
http://www.jbiomedsci.com/content/19/1/30
© 2012 Doss; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited.kilo bases (kb) of genomic DNA. It consists of 26 exons
and encodes a mature protein of 2,332 amino acids
arranged within six domains organized as A1-A2-BA3-
C1-C2 [4]. Its prevalence rate is estimated at 1:5,000-
10,000 in men. Factor VIII circulates in the blood as a
hetero dimer composed of two polypeptide chains: a
light chain with a molecular weight of 80,000 Daltons
(Da) and a heterogeneous heavy chain with a molecular
weight varying between 90,000 and 200,000, Daltons
(Da) both derived from the single peptide chain [5]. The
F9 gene is much smaller than F8 maps to the distal end
of the long arm of X-chromosome (Xq27) and spans 34
kb in length [6]. It contains 8 exons and encodes a gly-
coprotein of 415 amino acid residues, normally presents
in plasma, which is an essential component of the clot-
ting cascade [7]. It contains six major domains: signal
peptide, propeptide, gla domain, two epidermal growth
factor-like (EGF-like) domains, activation and catalytic
domains [8]. The heterogeneous genetic diseases Hae-
mophilia A & B, has been associated with missense
mutations, nonsense mutations, gene deletions of vary-
ing size, insertions, inversions, and splice junction muta-
tions and reported in Haemophilia A human database
[9] and Haemophilia B human Database [2]. Classifica-
tion of Haemophilia is based on plasma procoagulant
levels, with persons with less than 1% active factor (<
0.01 IU/ml) are classified as having severe haemophilia,
those with 1-5% active factor (0.01-0.05 IU/ml) have
moderate haemophilia, and those with 5-40% of normal
levels of active clotting factor (> 0.05- < 0.4 IU/ml) have
mild haemophilia [10].
Recent advances in high-throughput genotyping and
next generation sequencing have generated a tremen-
dous amount of human genetic variation data, deter-
mining the effects of amino acid substitution will be
the next challenge in mutation research. In the human
genome single base substitutions called ‘Single Nucleo-
tide Polymorphisms’ (SNPs) is the most frequent type
of genetic variation. When SNPs occur in coding
regions and produce amino acids change in the corre-
sponding proteins, we name it as nonsynonymous sin-
g l en u c l e o t i d ep o l y m o r p h i s m s( n s S N P s )[ 1 1 ] .H a l fo f
all genetic changes related to human diseases are
attributed to nsSNP variants [12]. Differentiating dele-
terious nsSNPs (significant phenotypic consequences)
from tolerant nsSNPs (without phenotypic change) are
of great importance in understanding the genetic basis
of haemophilias. This can be achieved by two general
strategies: (i) carrier detection by linkage analysis (ii)
in silico approach. Discriminating the types of nsSNPs
in Mendelian disease genes, coupled with issues of sta-
tistical power, provide a compelling rationale for the
application of a sequence-based approach to associa-
tion studies rather than complete reliance on a map of
anonymous haplotypes [13]. Because genome-wide
scans are still financially challenging, it is advantageous
to prioritize variants that may affect the structure or
function of expressed proteins. NsSNPs can be ana-
lyzed according to the biochemical severity of the
amino acid substitution and its context within the pro-
tein sequence. In this context, Grantham matrix [14]
predicts the effect of amino acid substitutions based
on chemical properties, including polarity and molecu-
lar volume. Recently more sophisticated in silico pro-
grams were developed and made available on the
World Wide Web [15-23]. They take into account, to
various degrees, factors such as the general rules of
protein chemistry (e.g., change in charge or in hydro-
phobicity, or helix-breaking residue), the three dimen-
sional structure of the protein, and homologies in
amino acid sequences among various species or related
proteins. These tools made use of a variety of features
such as information derived from protein sequences or
from both sequence and structural information. Dele-
t e r i o u sn s S N P sa n a l y s e sf o rt h eF8 and F9 genes have
not been estimated computationally till now, although
they have received great attention from experimental
researchers. To answer this question, in the absence of
other experimental investigations, we tested empirical
rule based methods PolyPhen (Polymorphism Pheno-
t y p i n g )a n dS o r t sI n t o l e r a n tF r o mT o l e r a n t( S I F T )
[11,20], machine-learning approach I-Mutant 2.0 [21],
UTRScan [22] and PupaSuite [23] were used for priori-
tization of high-risk SNPs in coding and non-coding
regions (5’ and 3’ un-translated regions (UTR) SNPs).
Based on the scores of SIFT, PolyPhen and I-Mutant,
we identified the deleterious nsSNPs that are likely to
affect the protein structure. In order to understand the
molecular mechanism of disease, it is important to
determine the impact of these mutations on the struc-
ture. We have identified the potential mutations, pro-
posed modeled structure for the mutant proteins, and
compared them with the native protein. We also ana-
lyzed native and mutant modeled protein for stability
analysis, solvent accessibility and secondary structure
analysis.
Methods
Extraction of SNP information
The SNPs information (Protein accession number (NP),
amino acid position, SNP ID, UniProtKB/Swiss-Prot
source ID, and mRNA accession number (NM) of F8
and F9 was retrieved from the NCBI dbSNP [24] and
SWISS-Prot databases [25] for our computational analy-
sis. The information on the effect and the relationship
between the nsSNPs and Haemophilia A and Haemo-
philia B disease was compiled from in vivo and in vitro
experiments according to PubMed, OMIM [26],
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base and UniProtKB/Swiss-Prot databases.
Assessment of nsSNP functionality
Empirical rules are derived based on sequence informa-
tion, structural information or both. These methods pre-
dict deleterious nsSNPs based on physicochemical
properties [14], protein structure [27-29], and cross spe-
cies conservation [28-30]. The SIFT [20] and PolyPhen
server [11] are the two representatives for this purpose.
SIFT
SIFT program http://blocks.fhcrc.org/sift/SIFT.html uses
“sequence homology to predict whether an amino acid
substitution will affect protein function and hence,
potentially alter phenotype”. SIFT scores are classified as
intolerant (0.00-0.05), potentially intolerant (0.051-0.10),
borderline (0.101-0.20), or tolerant (0.201-1.00) [31,32].
The higher a tolerance index, the less functional impact
a particular amino acid substitution is likely to have, as
a higher tolerance index indicates that the position is
less conserved across species.
PolyPhen
PolyPhen a multiple sequence alignment server that
aligns sequences using structural information. PolyPhen
performs the prediction through sequence-based charac-
terization of the substitution site, calculation of posi-
tion-specific independent count (PSIC) profile scores for
two amino acid variants, and calculation of structural
parameters and contacts. Theh i g h e raP S I Cs c o r ed i f -
ference, the higher functional impact a particular amino
acid substitution is likely to have. Predictions of how a
particular nsSNP may affect protein structure by Poly-
Phen 2.0 are assigned as “probably damaging” a score (≥
2.000) made with high confidence that the nsSNP
should affect protein structure and/or function; “possibly
damaging,” score (1.500-1.999) where it may affect pro-
tein function and/or structure; and “benign,” score
(0.000-0.999) as most likely having no phenotypic effect.
I-Mutant
I-Mutant 2.0 available at http://gpcr.biocomp.unibo.it/
cgi/predictors/I-Mutant2.0/I-Mutant2.0.cgi. is a support
vector machine (SVM)-based tool for the automatic pre-
diction of protein stability changes and stabilization cen-
ters upon single point mutations. I-Mutant 2.0
predictions are performed starting either from the pro-
tein structure or, more importantly, from the protein
sequence [21]. The output file shows the predicted free
energy change value or sign (DDG) which is calculated
f r o mt h eu n f o l d i n gG i b b sf r e ee n e r g yv a l u eo ft h e
mutated protein minus the unfolding Gibbs free energy
value of the native type (kcal/mol). If the DDG value is
positive then the mutated protein will have high stability
and vice versa for less stability. NsSNPs of F8 and F9
genes with experimental evidence of altered activity or
disease association were considered as deleterious. The
functional impact of the nsSNPs in F8 and F9 genes can
be validated from the phenotypic data obtained from
both in vivo and in vitro studies. Prediction accuracy of
these computational methods was analyzed based on the
positive findings from these benchmarking experiments
obtained from HAMSTeRS Database and Haemophilia
B database and UniProtKB/Swiss-Prot. nsSNPs predicted
as “deleterious” and experimentally associated was con-
sidered as correct, while the prediction was defined as
an error if such a deleterio u sn s S N Pw a sp r e d i c t e da s
tolerant. Concordance analysis between the functional
consequences of each nsSNP of F8 and F9 genes pre-
dicted by SIFT, PolyPhen and I-Mutant were assessed
using Spearman’s rank correlation coefficient r.
Predicting the molecular phenotypic effects of deleterious
SNPs
The PupaSuite 3.1 [23] are now synchronized to provide
annotations for both noncoding and coding SNPs, as
well as annotations for the SwissProt set of human dis-
ease mutations. PupaSuite finds all the SNPs mapping in
locations that might cause a loss of functionality in the
genes. PupasView [33] retrieves SNPs that could affect
conserved regions that the cellular machinery uses for
the correct processing of genes (intron/exon boundaries
or exonic splicing enhancers).
Characterization of SNPs in regulatory untranslated
regions
5’ and 3’ untranslated regions (UTR) of eukaryotic
mRNAs are involved in many posttranscriptional regula-
tory pathways that control mRNA localization, stability
and translation efficiency [34,35]. We used the program
UTRScan http://itbtools.ba.itb.cnr.it/utrscan for this ana-
lysis. UTRScan looks for UTR functional elements by
searching through user-submitted query sequences for
the patterns defined in the UTRsite collection. Briefly,
two or three sequences of each UTR SNP that have a
different nucleotide at an SNP position are analyzed by
UTRScan, which looks for UTR functional elements by
searching through user-submitted sequence data for the
patterns defined in the UTRsite and UTR databases. If
different sequences for each UTR SNP are found to
have different functional patterns, this UTR SNP is pre-
dicted to have functional significance.
Modeling nsSNP Locations on FVII and FIX
Structural analysis was performed based on the crystal
structure of the protein for evaluating the structural sta-
bility of native and mutant protein. We used the
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by F8 gene with PDB ID 2R7E[37] and F9 gene with
PDB ID 1RFN[38]. We also confirmed the mutation
p o s i t i o n sa n dt h em u t a t i o nr e s i d u e sf r o mt h i ss e r v e r .
These mutation positions and residues were in complete
agreement with the results obtained with SIFT and Poly-
Phen programs. Based on the position of amino acids in
the corresponding chains of the crystallized structures,
the mutation analysis was performed using SWISSPDB
viewer [39], and energy minimization was carried out
using the program package GROMACS 4.0.5 [40] with
Force field GROMOS96 43a1 [41]. The native and
mutant proteins were solvated in cubic 0.9 nm of simple
point charge (SPC) water molecules [42]. A periodic
boundary condition was applied that the number of par-
ticles, pressure, and temperature was kept constant in
the system. The system was neutralized by adding Na
+
and Cl
- ions around the molecules to obtain electrically
neutral system. The native and mutant structures were
first minimized with steepest descent by 2000 steps and
conjugated gradient by 3000. Computing total energy
gives information about the protein structure stability.
The deviation between the two structures is evaluated
by their RMSD (root mean square deviation) values
which could affect stability and functional activity [43].
By visualizing the position of the mutated amino acid
residues; it is possible to suggest a physiochemical ratio-
nale for the effect on protein activity. The quality of 3D
structure was assessed two programs: Verify 3D [44,45]
and Prosa-Web [46].
Analyzing the effects of mutations on protein stability
We obtained the solvent accessibility information using
program GETAREA [47] available at http://curie.utmb.
edu/getarea.html. For a successful analysis of the rela-
tion between amino acid sequence and protein struc-
ture, an unambiguous and physically meaningful
definition of secondary structure is essential. We
obtained the information about secondary structures of
the proteins using the program DSSP [48]. The predic-
tion of solvent accessibility and secondary structure has
been studied as an intermediate level for predicting the
tertiary structure of proteins.
Results
Predictions of deleterious and damaging coding nsSNPs
SNPs information for F8 and F9 was retrieved from
dbSNP and cross verified with Swiss-prot database. For
our investigations, we selected SNPs in nsSNPs and
UTR (5’and 3’) regions. Among the 675 nsSNPs, 510
nsSNPs (177 RefSNPs and 333 Swiss-Prot SNPs) and
165 nsSNPs (67 RefSNPs and 98 Swiss-Prot SNPs) were
in F8 and F9,1 7a n d9S N P si nm R N Ao fF8 and F9
were in included in our analysis. We applied three in
silico tools SIFT, PolyPhen and I-Mutant 2.0 to predict
the putative effect of each nsSNP on protein function.
F8
The protein sequences of 510 nsSNPs were submitted
separately to the SIFT program to inspect its tolerance
index. We identified a total of 378 nsSNPs (74%) that
were scored as intolerant by SIFT. Approximately 197
nsSNPs (39%) exhibited SIFT scores of 0.0; 181 nsSNPs
(35%) showed scores between 0.01-0.05; 9% of the var-
iants (45 nsSNPs) have scores between 0.051-0.10 and
the remaining 17% of the nsSNPs were classified as ‘Tol-
erant’ by SIFT. PolyPhen identified a total of 371
nsSNPs (73%) that were scored as damaging. 183
nsSNPs (36%) exhibited PolyPhen score of > 2.00, 188
nsSNPs (37%) have scores between 1.99-1.50, and 70
nsSNPs (13.5%) have scores between 1.49-1.25. Conse-
quently, 69 nsSNPs (13.5%) were characterized as
benign. We analyzed the nsSNPs finally by using I-
Mutant server. 445 nsSNPs (87%) were found to be less
stable and exhibited a DDG value ranging from -0.02 to
-5.23 respectively. Approximately 296 nsSNPs (58%)
showed a DDG value of ≤ -1.0; 169 nsSNPs (33%)
showed a DDG value -1.01 to -2.00 and the remaining
45 nsSNPs (9%) showed a DDG value ≥ -2.01 respec-
tively. Additional file 1: Table S1 represents the distribu-
tion of nsSNPs by SIFT, PolyPhen, and I-Mutant scores.
F9
Similarly, a total of 165 nsSNPs in F9 gene were sub-
mitted to SIFT, PolyPhen and I-Mutant 2.0. Additional
file 1: Table S1 represents the distribution of nsSNPs by
SIFT PolyPhen and I-Mutant 2.0 scores. By SIFT, 90
nsSNPs (55%) showed a tolerance index score of 0.00; 39
nsSNPs (24%) showed scores between 0.01-0.05; 7
nsSNPs (4%) showed scores between 0.051-0.10 and the
remaining 29 nsSNPs (17%) were classified as ‘Tolerant’
by SIFT. When PolyPhen was applied for prediction, 105
nsSNPs (64%) were scored as > 2.00; 26 nsSNPs (16%)
exhibited scores between 1.99-1.50, 8 nsSNPs (4.5%) have
scores between 1.49-1.25. Consequently, 69 nsSNPs
(15.5%) were characterized as benign. By I-Mutant, 82
nsSNPs (49.6%) showed a DDG value of ≤ -1.0; 55
nsSNPs (33%) showed a DDG value -1.01 to -2.00, 13
nsSNPs (7.9%) showed a DDG value ≥ -2.01, 15 nsSNPs
(9.1%) showed a DDG value < 0.00 respectively.
Correlation of computational methods in prediction of
nsSNPs in haemophliacs
We combined scores of different prediction programs
SIFT, PolyPhen, and I-Mutant 2.0 and found that this
could significantly increase prediction performance
nsSNPs analysis (Table 1). There are evidences to state
combinatorial approach using different computational
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diction of functional and deleterious nsSNPs [49]. Since a
lower SIFT or I-Mutant 2.0 score indicate that the nsSNPs
o fi n t e r e s tw o u l db em o r ed e l e t e r i o u s ,w h e r e a sah i g h e r
PolyPhen score indicate that the nsSNPs of interest would
be more deleterious. Among 510 nsSNPs in F8, 378
nsSNPs (74%) were predicted to be intolerant by SIFT,
371 nsSNPs (73%) were predicted to be damaging by Poly-
Phen and 445 nsSNPs (87%) as less stable by I-Mutant2.0.
In F9, 129 nsSNPs (78%) were predicted to be intolerant
by SIFT, 131 nsSNPs (79%) were predicted to be damaging
by PolyPhen and 150 nsSNPs (90%) as less stable by I-
Mutant2.0. By our analysis we found that I-Mutant out-
performed SIFT and PolyPhen in prediction of deleterious
nsSNPs in both F8 and F9. Most of these differences are
likely the result of each method requiring a sufficient
number and diversity of aligned sequences in order to
make a prediction, each method using a different set of
sequences and alignments. Our earlier analysis also shown
individual tools correlate modestly with observed results,
and that combining information from different tools may
perform better in increasing the predictive accuracy in
determining the functional impact of a given nsSNP [49].
In combination the nsSNPs which were predicted to be
deleterious in causing an effect in the structure and func-
tion of the protein by SIFT, PolyPhen, and I-Mutant 2.0
correlated well experimental studies as shown in Table S1
[50-130].
Predictions of potential phenotypic effect in SNPs
Among 29 SNPs predicted by PupaSuite, 26 nsSNPs were
found to disrupt Exon Splicing Enhancer and 3 nsSNPs
were predicted to disrupt Exon Splicing Silencer as
depicted in Additional file 1: Table S1 respectively. Four
SNPs namely rs1803603, rs34683807, rs1396947, and
rs5986887 were predicted to disrupt Exon Splicing Enhan-
cer and SNP namely rs34700571 was predicted to disrupt
Exon Splicing Silencer in untranslated region of F8 gene.
Functional SNPs in non-coding SNPs
Polymorphism in the 3’UTR region affects the gene
expression by affecting the ribosomal translation of
mRNA or by influencing the RNA half-life. UTResource
was applied to prioritize 17 SNPs (F8)a n d9S N P si n
(F9) UTR region. After comparing the functional ele-
ments for each UTR SNP, we found that only 5 SNPs
were predicted to have functional significance. Four
SNPs namely rs36101366, rs34683807, rs5986887,
rs1396947 were related to functional pattern change of
Upstream Open Reading Frame (UOF) and rs4487960
related to Polyadenylation Signal Upstream Open Read-
ing Frame (uORF) in F8,a n dt w oS N P sw i t hI D
rs191483077 and rs186616567 were related to functional
pattern change of Internal Ribosome Entry Site (IRES)
in F9 respectively.
Structural analysis
Single amino acid mutations can significantly alter the
stability of a protein structure. So, the knowledge of a
protein’s three-dimensional (3D) structure is essential
for a full understanding of its functionality. Mapping the
deleterious nsSNPs into protein structure information
was obtained from dbSNP and SAAPdb. Available X-ray
crystallized structures for the FVIII and FIX protein in
Protein Data Bank with PDB ID code 2R7E (3.70 Å),
and 2WPH (1.5 Å). Mutation analysis was performed
based on the results obtained from highest SIFT, and
PolyPhen scores. It is noted that rs34371500 (W274C),
VAR_028524 (W412R) in ‘A’ chain and rs28937299/
rs137852455 (W2065R), and VAR_028712 (W2332R) in
‘B’ chain of PDB ID 2R7E, showed the highest deleter-
ious score of 0.00 (SIFT) and damaging scores (Poly-
Phen) ranging from 3.318 to 3.543 respectively in FVIII.
Similarly in FIX, VAR_006611 (W431R), and
rs137852269 (W453R) showed the highest deleterious
score of 0.00 (SIFT) and damaging scores (PolyPhen) of
4.434 and 4.632 respectively. For W431R and W453R
mutation analysis was performed in the ‘S’ chain of the
PDB ID 2WPH. The mutations for FVIII and FIX at
their corresponding positions were performed by
SWISS-PDB viewer independently to achieve modeled
structures. Then, energy minimizations were performed
by GROMACS 4.0.5 for the native type protein and the
mutant type structures. Total energy and the RMSD
Table 1 Concordance analysis between SIFT and PolyPhen in the prediction of functional variants in F8 and F9
SIFT No of Variants PolyPhen No of Variants
Scores Prediction F8 F9 Scores Prediction F8 F9
0.00-0.05 Intolerant 378 129 ≥ 2.000 Probably damaging 183 105
0.051-0.10 Potentially intolerant 45 7 1.500-1.999 Possibly damaging 188 26
0.101-0.20 Borderline 43 8 1.25-1.49 Potentially damaging 70 8
0.201-1.00 Tolerant 44 21 1.00-1.24 Borderline 49 3
0.000-0.999 Benign 20 23
Total 510 165 Total 510 165
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mutant amino acids were calculated. Higher the RMSD
value more will be the deviation between native and
mutant type structures and which in turn changes their
functional activity. In this analysis found that the total
energy for the mutant proteins W274C, W412R,
W2065R, and W2332R following energy minimization
was -97899.13, -98142.42, -98013.21 and -97013.21 kJ/
mol when compared to native protein (2R7E) energy
-98911.33 kJ/mol. The RMSD values were calculated
between the native and mutant amino acids and showed
2.74 Å in W274C, 2.78 Å in W412R, 2.85 Å in W2065R
and 2.91 Å in W2332R. The superimposed structures of
the native protein with the four mutant type proteins
are shown in Figure 1a-d respectively. These figures
were drawn using PyMOL54 release 0.99 [131]. Simi-
larly, we checked the total energy for mutant type struc-
ture W431R and W453R were found to be -81428.83
and -81694.21 when compared to native energy of
-84591.35 kJ/mol. The RMSD values were calculated
between the native and mutant amino acids and showed
2.94 Å in W431R, and 3.18 Å in W453R. The superim-
posed structures of the native protein with the four
mutant type proteins are shown in Figure 2a-c, respec-
tively. In W412R, W2065R, W2332R W431R and
W453R there is change in drift of charge from non-
polar to polar residue Substitution of positively charged
arginine in place of neutral tryphtophan may lead to dis-
turbance in the interactions with other molecules or
other parts of the proteins. These types of substitutions
could introduce repulsive interactions between neigh-
boring residues. Similarly we observed the potential
effects of substitutions such as disruption of ligand
binding site, disruption of annotated functional site,
overpacking at buried site, contact with functional site,
and hydrophobicity change at buried site in PolyPhen
predictions. Solvent accessibilities and secondary struc-
tures of amino acid residues in the native and mutant
proteins were analyzed by GETAREA and DSSP as
shown in Table 2.
Discussion
Predicting phenotypic consequences of nsSNPs by
application of bioinformatics analysis may provide a
g o o dw a yt oe x p l o r et h ef u n c t i o no fn s S N P sa n dt h e
relationship between nsSNPs and susceptibility to dis-
ease. The mutations causing haemophilia A and B have
been localized and well characterized by several experi-
mental studies. Most of the mutations in haemophilias
leads to insufficient activity of the tenase complex,
brought about either by a deficiency of coagulation fac-
tor VIII cofactor activity (haemophilia A) or coagula-
tion factor IX enzyme activity (haemophilia B). Thus, it
is not surprising that the two disorders are clinically
D
E
F
G
H
Figure 1 Structural representation of FVIII (2R7E) native and
mutant proteins. a. Structure of FVIII native type protein (2R7E) in
grey displaying the position of W274, W412, W2065 and W2232 in
sphere shape (green color). b. Superimposed structure of native
amino acid tryptophan in sphere shape (green color) with mutant
amino acid cysteine (red color) at position 274 in ‘A’ chain of 2R7E.
c. Superimposed structure of native amino acid tryptophan in
sphere shape (green color) with mutant amino acid arginine (red
color) at position 412 in ‘A’ chain of 2R7E. d. Superimposed
structure of native amino acid tryptophan in sphere shape (green
color) with mutant amino acid arginine (red color) at position 2065
in ‘B’ chain of 2R7E. e. Superimposed structure of native amino acid
tryptophan in sphere shape (green color) with mutant amino acid
arginine (red color) at position 22232 in ‘B’ chain of 2R7E.
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the same essential step in the process of fibrin genera-
tion. It is also clearly evident the molecular basis of the
haemophilias is extremely diverse from the enormous
number of mutations that have been elucidated so far.
For this purpose, vast number of bioinformatic tools,
based on recent findings from evolutionary biology
(amino acid sequence), protein structure analysis, and
computational biology may provide useful information
in assessing the functional significance of SNPs have
been proposed. In this study, we explored the relation-
ship between prediction consequences of nsSNPs by
computational approaches based on recent findings
from evolutionary biology, protein structure research,
and real phenotypes confirmed by experiments. The
recent progress made in experimental 3D structure
determination of FVIII and FIX by X- ray crystallogra-
phy [37,38] and modeling studies [132] have made it
possible to predict the effects of nsSNPs at structural
level by mapping them on corresponding structures.
The functional consequences of most SNPs F8 and F9
gene are still unknown, although some nsSNPs have
been associated with X-linked inherited bleeding disor-
der. In vivo and in vitro studies on the function of
nsSNPs have found that genetic mutations in F8 and
F9 gene are responsible for Haemohpilia A and Hae-
mohpilia B. There have been a quite lot of studies
existing to validate the importance of single amino acid
substitutions in Haemophlia A and Haemophilia B at
activation cleavage sites [65,133,134], affecting factor
VIII binding to von Willebrand factor [65,101,135] fac-
tor VIII secretion [92] and factor IX binding to factor
VIII [136-138]. Recently Markoff by his homology
modeling approach analyzed the impact of substitu-
tions in loss of S-S bridges, thrombin activation site,
gain/loss of H-bonds, cross-chain H-bonds, ionic bond
and possible contact residue in FVIII [132]. The infor-
mation regarding the involvement of mutations in Gla
(g-carboxyglutamic acid) domain, EGF1 for the N-
terminal domain that binds calcium, EGF2 where it
does not bind calcium, and a catalytic serine protease
(SP) domain has been deposited in CoagMDB database
[138]. The most commonly observed amino acid sub-
stitutions are Arg, Tyr, Phe and Cys in FVIII and FIX
which play important role in altering the protein func-
tion. These amino acids are involved in protein folding
dependent on disulfide bonds (Cys) and protein active
or binding sites (Arg) [139,140]. These amino acids
predicted deleterious by SIFT, PolyPhen and I-Mutant
were in concordance with the experimental studies
(Additional file 1: Table S1). It is becoming clear that
implementation of the molecular evolutionary approach
may be a powerful tool for prioritizing SNPs to be gen-
otyped in future molecular epidemiological studies.
D
E
F
Figure 2 Structural representation of FIX (2WPH) native and
mutant proteins. a. Structure of FIX native type protein (2WPH) in
grey displaying the position of W431 and W453 in sphere shape
(green color). b. Superimposed structure of native amino acid
tryptophan in sphere shape (green color) with mutant amino acid
arginine (red color) at position 412 in ‘S’ chain of 2WPH. c.
Superimposed structure of native amino acid tryptophan in sphere
shape (green color) with mutant amino acid arginine (red color) at
position 453 in ‘S’ chain of 2WPH.
C Journal of Biomedical Science 2012, 19:30
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Page 7 of 12Moreover, from an evolutionary perspective, SNPs
altering a conserved amino acid site are more likely to
have functional importance. Computational tools like
SIFT and PolyPhen are able to predict 90% of dama-
ging SNPs. Several groups also validated these algo-
rithms has, however, come from benchmarking studies
based on the analysis of “known” deleterious substitu-
tions annotated in databases, such as SwissProt. In
such studies, PolyPhen and SIFT has been shown to
successfully predict the effect of over 80% of amino
acid substitutions [31,32,141]. In this study, we first
surveyed previous publications and submitted muta-
tions in database associated with Haemophilia A and
Haemophilia B, the most extensively examined bleeding
disorder. In this present study three different widely-
used computational tools were employed for determin-
ing the functional significance of nsSNPs. First, we
included functional scores from SIFT, PolyPhen and I-
Mutant tools, each of which employs fundamentally
different algorithms that can be used to determine the
functionality of the same nsSNPs. Proteins with muta-
tions do not always have 3D structures that are solved
and deposited in PDB. Therefore, it is necessary to
construct 3D models using homology modeling by
locating the variation in 3D. This is a simple way of
detecting what kind of adverse effects that a mutation
can have on a protein.
Based on the SIFT, PolyPhen, and I-Mutant scores
and availability of 3D structures, structure analysis
was carried out with the major mutation that occurred
i nt h en a t i v ep r o t e i nc o d e db yF8 and F9. The total
energy and RMSD value of mutant structures W274C,
W412R, W2065R, W2332R, W431R, and W453R were
calculated. Correlations between SIFT (Sensitivity
83%), PolyPhen (Sensitivity 82%) and I Mutant (Sensi-
tivity 80%) were calculated from raw scores rather
than the arbitrarily defined categories. There was a
significant correlation between the predictions
obtained using SIFT and PolyPhen algorithms in both
F8 (r = -0.59) and F9 (r = -0.576); while the correla-
tion between the predictions obtained using PolyPhen
and I Mutant in F8 (r = -0.86) and F9 (r = -0.63)
were much higher. A positive correlation was observed
with SIFT and I- Mutant score for F8 (r =0 . 3 0 )a n d
F9 (r =0 . 3 1 ) .W eh a v es h o w nt h a to u rd a t as u g g e s t s
that different tools correlate modestly with observed
r e s u l t s ,a n dt h a tc o m b i n i n ginformation from a variety
of tools may significantly increase the predictive
power for determining the functional impact of a
given nsSNP.
Table 2 Solvent accessibilities and Secondary structure analysis in the native and mutant proteins
Mutation
Position
Solvent accessibility in the native and mutant proteins by GETAREA Secondary structure analysis by DSSP
Changed from exposed to buried Changed from buried to exposed
W274C Thr (2), Tyr(5) Leu(7), Val(63), His(76), Ala(81),
Pro(93), Ser(116), Ala(119), Glu(129), Lys(146),
Tyr(155), Lys(185), Leu(187), Ala(194), Lys(213),
Leu (217), Ile(310), Leu(319), Leu(327), Gln(335),
Glu(340), Lys(344), Pro(349), Lys(399), Thr(400),
Leu(419), Tyr(426), Lys(431), Lys(441), Ala(449),
Thr(454), Lys(485), Arg(509), Gly(539), Thr(549),
Ser(553), Glu(559), Glu(576), Asp(579), Gln(585),
Lys(589), Val(592), Phe(598), Arg(602), Leu(614),
Asn(631), Tyr(639), Ser(647), Ala(654), His(679),
Leu(689), Val(697), Asn(713), Arg(719), Ser(728),
Lys(732)
Trp(14), Leu(69), Gln(96), Val(99), Ser(138), Ser
(176), Ser(179), Ile(405), Asn(299), Cys(329), Val
(392), Arg(424), Tyr(473), Arg(503), Arg(546),
Val(556), Pro(569), Gly(565), Asn(609), Gly(619),
Ile(636), Trp(707)
T ® H: Pro(86), Gly(89), Leu(203), Thr
(208), Ser(428), Lys(518), Gly(638), His
(1735), Thr(1763), Lys(1932), Asn(1934),
Met(1945), Glu(2200)
H ® T:Lys(161), Lys(185), Leu(187), Leu
(562), Asn(601), Glu(608), Arg(612), Ser
(630), Asp(1865), Gly(2022)
T ® S:Trp(87), Leu(517), Asn(637), Asn
(1772)
W2065R Asp(1260), Gln(1336), Leu(1481), Ala(1610), Ile
(1698), Tyr(1699), Arg(1708), Thr(1714), Glu
(1723), Arg(1740), Gly(1769), Leu(1775), Ile
(1782), Arg(1800), His(1867), Leu(1882), Trp
(1908), Ala(1939), Asn(1941), Met(1945), Arg
(1960), Ser(1968), Asn(1971), Phe(1982), Met
(2007), Arg(2016), Ser(2082), Arg(2169)
Asn(1460), Gln(1705), Gly(1779), Leu(1808), Val
(1876), Glu(1884), Glu(1904), Met(1842), Ile
(1901), Tyr(1909), Thr(2015),
T ® H:), His(1735), Thr(1763), Lys(1932),
Asn(1934), Met(1945), Glu(2200)
H ® T: Asp(1865), His(1867), Asp(2206)
T ® S: Asn(1772)
W2248C Asp(1260), Gln(1336), Asn(1460), Leu(1481), Ala
(1610), Ile(1698), Tyr(1699), Arg(1708), Thr
(1714), Glu(1723), Arg(1740), Gly(1769), Leu
(1775), Ile(1782), Arg(1800), His(1867), Val(1876),
Leu(1882), Trp(1908), Ala(1939), Asn(1941), Met
(1945), Arg(1960), Ser(1968), Asn(1971), Phe
(1982), Met(2007), Arg(2016), Gly(2028), Ala
(2070)Ser(2082), Arg(2169)
Asn(1460), Gln(1705), Gly(1779), Leu(1808), Val
(1876), Glu(1884), Glu(1904), Met(1842), Ile
(1901), Tyr(1909), Thr(2015), Gly(2022), Ala
(2070)
T ® H:), His(1735), Thr(1763), Lys(1932),
Asn(1934), Met(1945), Glu(2200)
H ® T: Asp(1865), Gly(2022)
T-Turn, H-Helix, S-Strand
C Journal of Biomedical Science 2012, 19:30
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In conclusion, from our in silico analysis it is very diffi-
cult to determine whether the notable differences exists
in the performance of these methods in predicting dele-
t e r i o u sn s S N P si nF8 and F9. The variation in the pre-
diction might be due to the difference in features
utilized by the methods or the training datasets. There
is no single literature stating a single in silico method
can aid in better prediction. Our in silico analysis coin-
c i d e sw i t hp r e v i o u sa n a l y s i sp e r f o r m e db yo t h e rg r o u p s
stating that combining information obtained from var-
ious methods can increase prediction performance. The
overall strategy of our study was to prioritize the func-
tional nsSNPs, map as many structural mutations as
possible, find general patterns to analyze 3D mutations
with respect to protein function and evaluate regulatory
variants using many in silico analysis methods as possi-
ble. Based on these analyses, we try to determine the
relationship between the disease-related mutations and
structural properties of proteins in haemophiliacs.
Additional material
Additional file 1: Table S1. List of nsSNPs found to be functionally
significant by SIFT, PolyPhen, I-Mutant and PupaSuite.
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